Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paola Valeria Marchese
Observed names:
P. Marchese,
P.V. Marchese,
PAOLA VALERIA MARCHESE,
Paola V. Marchese
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
Observed institutions:
University of Rome Tor Vergata,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
ORCID:
0000-0002-1309-2819
Observed ORCID:
0000-0002-1309-2819
OpenAlex ID:
A5009893126
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
2022
·
Elisa Andrini
, Paola Valeria Marchese
, et al.
·
Journal of Clinical Medicine
·
89
PDF
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
2023
·
Valentina Tateo
, Paola Valeria Marchese
, et al.
·
Pharmaceuticals
·
77
PDF
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
2021
·
Filippo G. Dall’Olio
, Diletta Calabrò
, et al.
·
European Journal of Cancer
·
56
Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer
2018
·
PAOLO ORSARIA
, AGOSTINO CHIARAVALLOTI
, et al.
·
Anticancer Research
·
38
PDF
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
2023
·
Maria Concetta Nigro
, Paola Valeria Marchese
, et al.
·
Lung Cancer Targets and Therapy
·
25
PDF
Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel
2024
·
Thais Maloberti
, Antonio De Leo
, et al.
·
Diagnostics
·
12
PDF
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers
2022
·
Paola Valeria Marchese
, Veronica Mollica
, et al.
·
Expert Review of Molecular Diagnostics
·
10
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy
2024
·
Nadia Saoudi González
, Paola Valeria Marchese
, et al.
·
Expert Opinion on Investigational Drugs
·
9
Defining high-risk patients: beyond the 8the AJCC melanoma staging system
2024
·
Elisabetta Broseghini
, Giulia Veronesi
, et al.
·
Archives of Dermatological Research
·
7
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population‐based analysis
2022
·
Giuseppe Lamberti
, Elisa Andrini
, et al.
·
Cancer Medicine
·
7
PDF
Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
2022
·
Filippo G. Dall’Olio
, Claudia Parisi
, et al.
·
Therapeutic Advances in Medical Oncology
·
7
PDF
Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy
2025
·
Federico Venturi
, Elisabetta Magnaterra
, et al.
·
Diagnostics
·
6
PDF
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy
2024
·
Andrea De Giglio
, Alessandro Leonetti
, et al.
·
Cancer Immunology Immunotherapy
·
6
PDF
Calcitonin-secreting neuroendocrine tumor of the larynx, a diagnostic challenge of a rare neoplasm: a case report and literature review
2024
·
Daria Maria Filippini
, Andi Abeshi
, et al.
·
AME Case Reports
·
5
Systemic and Liver-Directed Therapies in Metastatic Uveal Melanoma: State-of-the-Art and Novel Perspectives
2021
·
Francesca Comito
, Paola Valeria Marchese
, et al.
·
Future Oncology
·
5
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
2023
·
Veronica Mollica
, Elisa Tassinari
, et al.
·
Pathology - Research and Practice
·
4
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
2022
·
Paola Valeria Marchese
, Veronica Mollica
, et al.
·
Pathology - Research and Practice
·
3
Should Fertility Preservation Be Offered to Young Women with Melanoma Receiving Immune Checkpoint Inhibitors? A SWOT Analysis
2025
·
Diego Raimondo
, Michele Miscia
, et al.
·
Current Oncology
·
2
Rapid radiological response of leptomeningeal carcinosis and prolonged survival to encorafenib and binimetinib in BRAF-mutated melanoma
2025
·
Giacomo Corradi
, Sara De Martino
, et al.
·
Anti-Cancer Drugs
·
1
107P Baseline total metabolic tumour volume on [18F]FDG PET/CT as promising biomarker in advanced NSCLC patients treated with first line pembrolizumab
2021
·
F.G. Dall'Olio
, D. Calabrò
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors
2026
·
PAOLA VALERIA MARCHESE
, IRENE ZANNINI
, et al.
·
Anticancer Research
Prognostic value of different metabolic response criteria in patients with advanced melanoma treated with immunotherapy: a comparative analysis of PECRIT, PERCIMT, and EORTC criteria
2026
·
Andrea Di Giorgio
, Francesca Comito
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
Thin Nevus-Associated Melanoma: Beyond MIA Score Risk Stratification
2026
·
Federico Venturi
, Maria Luisa Orlando
, et al.
·
Cancers
PDF
Complete response with combined sonidegib and pembrolizumab in synchronous advanced basal cell carcinoma and metastatic cutaneous squamous cell carcinoma: A case report
2026
·
Paola Valeria Marchese
, Carolina Ortiz
, et al.
·
EJC Skin Cancer
PDF
1355P Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
2021
·
F.G. Dall'Olio
, C. Parisi
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
25
Citation count:
370
H-index:
8
I10-index:
7
Year
Topic
Type